"Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report by DelveInsight offers comprehensive insights on marketed and Phase III products for Relapsing Multiple Sclerosis (RMS). The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for United States, Europe, China, and India. The report also covers the emerging Phase III pipeline assets for Relapsing Multiple Sclerosis (RMS) including their detailed product profiles.
Additionally, the report also highlights the future competitive landscape for Relapsing Multiple Sclerosis (RMS) therapeutics. Depending on information availability comprehensive coverage of the following for Relapsing Multiple Sclerosis (RMS) marketed products for Relapsing Multiple Sclerosis (RMS) descriptive marketed product profiles for Relapsing Multiple Sclerosis (RMS) including (but not limited to) drug description, regulatory milestones, product development and R&D activities encompassing clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are the historical and forecasted global sales till 2023 for each product.
Global API Manufacturers of marketed products for Relapsing Multiple Sclerosis (RMS) coverage of API manufacturers for Relapsing Multiple Sclerosis (RMS) marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers name along with their location Emerging Phase III products for Relapsing Multiple Sclerosis (RMS) descriptive Phase III product profiles for Relapsing Multiple Sclerosis (RMS) including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also their forecasted global sales are provided till 2023.
The report provides insights into:
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.
This report provides an in-depth commercial assessment of marketed products, which comprises the details of collaborations, licensing, acquisition - deal value trends, patent and global sales.
The report comprises of comparative clinical assessment of products by development stage, route of administration and molecule type across this indication.
1. Report Introduction
2. Relapsing Multiple Sclerosis (RMS)
2.1. Relapsing Multiple Sclerosis (RMS) Symptoms
2.2. Relapsing Multiple Sclerosis (RMS) Causes
2.3. Relapsing Multiple Sclerosis (RMS) Types
2.4. Relapsing Multiple Sclerosis (RMS) Risk Factors / Complications
2.5. Relapsing Multiple Sclerosis (RMS) Pathophysiology
2.6. Relapsing Multiple Sclerosis (RMS) Diagnosis
2.7. Relapsing Multiple Sclerosis (RMS) Treatment
3. Comparative Analysis of Marketed and Emerging Products
3.1. Marketed Products
3.1.1. Drug A: Company
3.1.1.1. Product Description
3.1.1.2. Regulatory Milestones
3.1.1.3. Product Development Activities
3.1.1.3.1. General Description Table
3.1.1.4. Global Sales
3.1.1.5. Global API Manufacturers for Drug A
3.1.1.5.1. United States
3.1.1.5.2. Europe
3.1.1.5.3. China
3.1.1.5.4. India
3.1.2. Drug B: Company
3.1.2.1. Product Description
3.1.2.2. Regulatory Milestones
3.1.2.3. Product Development Activities
3.1.2.3.1. General Description Table
3.1.2.4. Global Sales
3.1.2.5. Global API Manufacturers for Drug B
3.1.2.5.1. United States
3.1.2.5.2. Europe
3.1.2.5.3. China
3.1.2.5.4. India
Complete details in the report
3.1.3. Emerging Therapies - Late Phase
3.1.3.1. List of Phase III drugs for Relapsing Multiple Sclerosis (RMS)
4. Appendix
5. Report Methodology
5.1. Secondary Research
5.2. Expert Panel Validation
Table 1 : List of Marketed and Emerging Products
Table 2 : Drug A Annual Global Sales from 2012-2023 (in USD million)
Table 3 : API Manufacturers for Drug A Region wise
Table 4 : API Manufacturers for Drug A for the United States
Table 5 : API Manufacturers for Drug A for Europe
Table 6 :/ API Manufacturers for Drug A for India
Table 7 : API Manufacturers for Drug A for China
Table 8 : Drug B Annual Global Sales from 2012-2023 (in USD million)
Table 9 : API Manufacturers for Drug B Region wise
Table 10 : API Manufacturers for Drug B for the United States
Table 11 : API Manufacturers for Drug B for Europe
Table 12 : API Manufacturers for Drug B for India
Table 13 : API Manufacturers for Drug B for China
Table 14 : Drug C Annual Global Sales from 2014-2023 (in USD million)
Table 15 : API Manufacturers for Drug C Region wise
Table 16 : API Manufacturers for Drug C for the United States
Table 17 : API Manufacturers for Drug C for Europe
Table 18 : API Manufacturers for Drug C for India
Table 19 : API Manufacturers for Drug C for China
Table 20 : Drug D, Annual Global Sales from 2013-2023 (in USD million)
Table 21 : API Manufacturers for Drug D Region wise
Table 22 : API Manufacturers for Drug D for the United States
Table 23 : API Manufacturers for Drug D for Europe
Table 24 : API Manufacturers for Drug D for India
Table 25 : API Manufacturers for Drug D for China
Table 26 : Drug E Annual Global Sales from 2014-2023 (in USD million)
Table 27 : API Manufacturers for Drug E Region wise
Table 28 : API Manufacturers for Drug E for the United States
Table 29 : API Manufacturers for Drug E for Europe
Table 30 : API Manufacturers for Drug E for India
Table 31 : API Manufacturers for Drug E for China
Table 32 : List of Phase III drugs for Relapsing Multiple Sclerosis (RMS)
Figure 1 : Comparative Analysis of Marketed and Emerging Products
Figure 2 : Drug A, Annual Global Sales from 2012-2023 (in USD million)
Figure 3 : API Manufacturers for Drug A Region wise
Figure 4 : Drug B, Annual Global Sales from 2012-2023 (in USD million)
Figure 5 : API Manufacturers for Drug B Region wise
Figure 6 : Drug C, Annual Global Sales from 2014-2023 (in USD million)
Figure 7 : API Manufacturers for Drug C Region wise
Figure 8 : Drug D, Annual Global Sales from 2011-2023 (in USD million)
Figure 9 : API Manufacturers for Drug D Region wise
Figure 10 : Drug E, Annual Global Sales from 2014-2023 (in USD million)
Figure 11 : API Manufacturers for Drug E Region wise
